Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. A 52-week randomised, double-blind, active- and placebo-controlled trial

X
Trial Profile

Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. A 52-week randomised, double-blind, active- and placebo-controlled trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary) ; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PIONEER 4
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 May 2023 Results of a post-hoc analysis from clinical trials: PIONEER 1-5 and 8 assessing clinically relevant composite endpoints of HbA1c (glyclated haemogloblin) reduction published in the Diabetes Therapy
    • 09 Nov 2022 Results assessing the long-term cost-effectiveness of immediate oral semaglutide treatment versus continuing metformin plus SGLT-2 inhibitor therapy in the United kingdom from PIONEER 4, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 23 Sep 2022 Results of an exploratory analysis assessing time spent by patients with HbA1c <7.0% (53 mmol/mol), and likelihood of maintaining this glycaemic control using data from four clinical studies: PIONEER-2, PIONEER-3, PIONEER-4 and PIONEER-7 presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top